Processa Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Processa Pharmaceuticals, Inc. (PCSA) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price of $13.43 per share as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice · last filed 2026-08-14
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $13.43.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $13.43.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $13.43.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $10235.31; Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price as first filed $409.09.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2026-06-30 | $13.43 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $13.43 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $13.43 10-Q · filed 2026-08-14 | |
| 2024-12-31 | $10235.31 10-K · filed 2026-03-18 | $409.09 10-K · filed 2025-03-20 |
| 2023-12-31 | $9080.65 10-K · filed 2026-03-18 | $364.72 10-K · filed 2025-03-20 |
| 2022-12-31 | $341.34 10-K · filed 2025-03-20 | |
| 2021-12-31 | $341.34 10-K · filed 2024-03-29 | $17.07 10-K · filed 2022-03-30 |
| 2020-12-31 | $18.11 10-K · filed 2023-03-30 | |
| 2019-12-31 | $17.93 10-K · filed 2022-03-30 | |
| 2018-12-31 | $20.45 10-K · filed 2021-03-25 | $2.92 10-K · filed 2019-03-28 |
| 2018-09-30 | $2.84 10-Q · filed 2018-11-14 | |
| 2017-06-30 | $1.89 10-Q · filed 2017-10-04 | |
| 2017-03-31 | $1.90 10-Q · filed 2017-10-04 | |
| 2016-12-31 | $1.88 10-Q · filed 2017-11-20 | |
| 2016-09-30 | $1.88 10-Q · filed 2017-09-08 | |
| 2016-06-30 | $1.94 10-Q · filed 2017-08-30 | |
| 2016-03-31 | $1.94 10-Q · filed 2017-08-07 | |
| 2015-12-31 | $1.78 10-K · filed 2017-09-25 | |
| 2015-09-30 | $1.87 10-Q · filed 2015-12-01 | |
| 2015-06-30 | $1.87 10-Q · filed 2015-08-19 | |
| 2015-03-31 | $2.34 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $2.35 10-K · filed 2017-09-25 | |
| 2014-09-30 | $2.40 10-Q · filed 2014-11-13 | |
| 2014-06-30 | $2.39 10-Q · filed 2014-08-19 | |
| 2014-03-31 | $2.35 10-Q · filed 2014-05-14 | |
| 2013-12-31 | $2.23 10-K · filed 2017-06-19 | |
| 2013-09-30 | $2.01 10-Q · filed 2013-11-08 | |
| 2013-06-30 | $2.01 10-Q/A · filed 2013-09-06 | |
| 2012-12-31 | $2.00 10-K · filed 2015-04-14 | |
| 2011-12-31 | $2.00 10-K · filed 2014-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |